Clinical Trials Browser

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT07001384 2026-04-08

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT05044039 2026-02-02

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Phase 1 Active not recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Phase 1 Active not recruiting

114 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Phase 1 Completed

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04836832 2022-06-07

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1 Completed

48 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

Clinical Trials

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies